47154 Federal Register / Vol. 78, No. 150 / Monday, August 5, 2013 / Rules and Regulations 

(b) Determination of claims—(1) 

Delegation of authority to determine 

claims. The General Counsel, and such 

employees of the Legal Division as the 

General Counsel may designate are 

authorized to consider, ascertain, adjust, 

determine, compromise, and settle 

claims pursuant to the FTCA, as 

amended, and the regulations contained 

in 28 CFR part 14 and in this section. 

(2) Disallowance of claims. If the 

General Counsel, or the General 

Counsel’s designee, denies a claim, the 

General Counsel or designee shall notify 

the claimant, or the claimant’s duly 

authorized agent or legal representative. 

Dated: July 11, 2013. 

Richard Cordray, 

Director, Bureau of Consumer Financial 

Protection. 

[FR Doc. 2013–18844 Filed 8–2–13; 8:45 am] 

BILLING CODE 4810–AM–P 

COMMODITY FUTURES TRADING 

COMMISSION 

17 CFR Part 37 

RIN 3038–AD18 

Core Principles and Other 

Requirements for Swap Execution 

Facilities; Correction 

AGENCY: Commodity Futures Trading 

Commission. 

ACTION: Final rule; correction. 

SUMMARY: The Commodity Futures 

Trading Commission is correcting a 

final rule that appeared in the Federal 

Register of June 4, 2013 (78 FR 33476). 

The final rule applies to the registration 

and operation of a new type of regulated 

entity named a swap execution facility, 

and implements provisions of the DoddFrank Wall Street Reform and Consumer 

Protection Act. 

DATES: The effective date of this 

correction is August 5, 2013. 

FOR FURTHER INFORMATION CONTACT: 

Amir Zaidi, Special Counsel, Division of 

Market Oversight, Commodity Futures 

Trading Commission, Three Lafayette 

Center, 1155 21st Street NW., 

Washington, DC 20581; 202–418–6770; 

azaidi@cftc.gov. 

SUPPLEMENTARY INFORMATION: In FR Doc. 

2013–12242 appearing on page 33476 in 

the Federal Register of Tuesday, June 4, 

2013, the following corrections are 

made: 

§ 37.702 [Corrected] 

1. On page 33591, in the second 

column, in § 37.702 General financial 

integrity, paragraph (b) is corrected to 

read as follows: 

(b) For transactions cleared by a 

derivatives clearing organization: 

(1) By ensuring that the swap 

execution facility has the capacity to 

route transactions to the derivatives 

clearing organization in a manner 

acceptable to the derivatives clearing 

organization for purposes of clearing; 

and 

(2) By coordinating with each 

derivatives clearing organization to 

which it submits transactions for 

clearing, in the development of rules 

and procedures to facilitate prompt and 

efficient transaction processing in 

accordance with the requirements of 

§ 39.12(b)(7) of this chapter. 

Appendix B to Part 37—Guidance on, 

and Acceptable Practices in, 

Compliance With Core Principles 

[Corrected] 

2. On page 33600, in the second 

column, under the heading Core 

Principle 3 of Section 5h of the Act— 

Swaps Not Readily Susceptible to 

Manipulation, in paragraph (a)(3), 

correct the reference to ‘‘section c(5)’’ to 

read ‘‘section c(4).’’ 

Dated: July 31, 2013. 

Christopher J. Kirkpatrick, 

Deputy Secretary of the Commission. 

[FR Doc. 2013–18773 Filed 8–2–13; 8:45 am] 

BILLING CODE 6351–01–P 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

Food and Drug Administration 

21 CFR Part 101 

[Docket No. FDA–2005–N–0404] 

RIN 0910–AG84 

Food Labeling; Gluten-Free Labeling of 

Foods 

AGENCY: Food and Drug Administration, 

HHS. 

ACTION: Final rule. 

SUMMARY: The Food and Drug 

Administration (FDA or we) is issuing a 

final rule to define the term ‘‘glutenfree’’ for voluntary use in the labeling of 

foods. The final rule defines the term 

‘‘gluten-free’’ to mean that the food 

bearing the claim does not contain an 

ingredient that is a gluten-containing 

grain (e.g., spelt wheat); an ingredient 

that is derived from a gluten-containing 

grain and that has not been processed to 

remove gluten (e.g., wheat flour); or an 

ingredient that is derived from a glutencontaining grain and that has been 

processed to remove gluten (e.g., wheat 

starch), if the use of that ingredient 

results in the presence of 20 parts per 

million (ppm) or more gluten in the 

food (i.e., 20 milligrams (mg) or more 

gluten per kilogram (kg) of food); or 

inherently does not contain gluten; and 

that any unavoidable presence of gluten 

in the food is below 20 ppm gluten (i.e., 

below 20 mg gluten per kg of food). A 

food that bears the claim ‘‘no gluten,’’ 

‘‘free of gluten,’’ or ‘‘without gluten’’ in 

its labeling and fails to meet the 

requirements for a ‘‘gluten-free’’ claim 

will be deemed to be misbranded. In 

addition, a food whose labeling includes 

the term ‘‘wheat’’ in the ingredient list 

or in a separate ‘‘Contains wheat’’ 

statement as required by a section of the 

Federal Food, Drug, and Cosmetic Act 

(the FD&C Act) and also bears the claim 

‘‘gluten-free’’ will be deemed to be 

misbranded unless its labeling also 

bears additional language clarifying that 

the wheat has been processed to allow 

the food to meet FDA requirements for 

a ‘‘gluten-free’’ claim. Establishing a 

definition of the term ‘‘gluten-free’’ and 

uniform conditions for its use in food 

labeling will help ensure that 

individuals with celiac disease are not 

misled and are provided with truthful 

and accurate information with respect to 

foods so labeled. We are issuing the 

final rule under the Food Allergen 

Labeling and Consumer Protection Act 

of 2004 (FALCPA). 

DATES: Effective date: The final rule 

becomes effective on September 4, 2013. 

Compliance date: The compliance date 

of this final rule is August 5, 2014. See 

section II.B.4 (comment 35 and response 

35) for an additional explanation of the 

compliance date and implementation of 

this final rule. 

FOR FURTHER INFORMATION CONTACT: 

Felicia B. Billingslea, Center for Food 

Safety and Applied Nutrition (HFS– 

820), Food and Drug Administration, 

5100 Paint Branch Pkwy., College Park, 

MD 20740, 240–402–2371, FAX: 301– 

436–2636, email: GlutenFreeFinalRule

Questions@fda.hhs.gov. 

SUPPLEMENTARY INFORMATION: 

Executive Summary 

Purpose of the Rule 

Need for the rule: Celiac disease is a 

hereditary, chronic inflammatory 

disorder of the small intestine triggered 

by the ingestion of certain storage 

proteins referred to as gluten occurring 

in wheat, rye, barley, and crossbreeds of 

these grains. Celiac disease has no cure, 

but individuals who have this disease 

are advised to avoid all sources of 

gluten in their diet to protect against 

adverse health effects associated with 

the disease. Many manufacturers 

currently label their food with a 

mstockstill on DSK4VPTVN1PROD with RULES